Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

類似資料

• Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
  著者:: Li, Xuefei, 等
  出版事項: (2016)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  著者:: Jia, Yijun, 等
  出版事項: (2020)
• Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
  著者:: Yang, Shuo, 等
  出版事項: (2021)
• Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
  著者:: Juan Zhou, 等
  出版事項: (2019-04-01)
• Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
  著者:: Zhou, Juan, 等
  出版事項: (2019)